Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA4P in Advanced Anaplastic Thyroid Cancer
NCT00060242Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Feb 2003
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosbretabulin in anaplastic thyroid cancer (ATC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Median survival. Started Feb 2003; status: completed.
02
Drugs
fosbretabulin
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT00060242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060242.